Cassava Sciences

News

FTC says Shkreli is flouting lifetime pharma ban

The FTC and several US states have accused Martin Shkreli of violating a lifetime order preventing him from involvement in the pharma industry.

News

End of the line for Cassava's troubled Alzheimer's programme

The saga of Cassava Sciences' development of Alzheimer's disease therapy simufilam has come to its dismal end.

News

End looms for Cassava's simufilam in Alzheimer's disease

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the end

R&D

Cassava’s Alzheimer’s drug nears P3 readout, but SEC scandal...

Cassava is advancing simufilam through a pivotal phase 3 trial, despite lingering controversy from a SEC investigation.

News

SEC charges Cassava over 'misleading' Alzheimer's claims

The US financial regulator has accepted a $40 million-plus settlement from Cassava Sciences and two of its former executives for making what it alleges are misleading statements about the r

FTC says Shkreli is flouting lifetime pharma ban

End of the line for Cassava's troubled Alzheimer's programme

End looms for Cassava's simufilam in Alzheimer's disease

Cassava’s Alzheimer’s drug nears P3 readout, but SEC scandal...

SEC charges Cassava over 'misleading' Alzheimer's claims

Aspen, Bambusa close IPOs as Corxel takes SPAC route

Discover a new era of healthcare panel engagement: Grounded ...

Cassava Sciences

Editor's Picks